BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2006

View Archived Issues

FabI inhibitors shown effective against staphylococci

Read More

AN-0900's encouraging results in preclinical models of anthrax infection

Read More

ATH-18534: targets pneumonia bacterial pathogenicity

Read More

Hemispherx Biopharma reports on "excellent year"

Read More

Dusa to acquire Sirius Laboratories

Read More

Fast track designation for HuMax-EGFr in head and neck cancer

Read More

Wyeth and Trubion form strategic alliance in inflammatory disease and cancer

Read More

Bristol-Myers Squibb files sBLA for third-party manufacturing of Orencia

Read More

Sativex cleared for U.S. phase III trials

Read More

Neose Technologies cleared to study NE-180 in phase I trial

Read More

Morphotek inlicenses antibody for mesothelin-expressing cancers

Read More

Versatile topical DNA vaccine undergoes preliminary clinical study in HIV

Read More

Northfield to receive defense appropriation for PolyHeme development

Read More

Orphan drug designation for CellCept in myasthenia gravis

Read More

Ecopia BioSciences seeks clearance for phase I Canadian study of ECO-4601

Read More

Epix ramps up phase IIa study of fibrin-binding imaging agent EP-2104R

Read More

Bayer purchases GlaxoSmithKline's European telmisartan rights

Read More

Gardasil submitted for Australian approval

Read More

KW-3902 improves fluid elimination and renal function in heart failure patients

Read More

Novel agents with potential in the treatment of anxiety, depression, etc. revealed in recent patents

Read More

Climara Pro approved for prevention of postmenopausal osteoporosis

Read More

Recent patents describe possible new agents for diabetes

Read More

Phase II trial investigates iPlex for myotonic muscular dystrophy

Read More

Novel treatments for cancer subject of several recent patents

Read More

Phase II trial for NT-501 in dry AMD

Read More

Success of universal toddler Havrix(R) vaccination program in endemic hepatitis A population

Read More

Synergistic antidepressant effects seen with M-100907 and fluoxetine

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 17, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing